Dialysis Products

Rockwell Medical is a fully integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency anemia, secondary hyperparathyroidism and hemodialysis throughout the U.S. and abroad. Learn more 

Bio-Pharma Development Program

The company’s lead bio-pharmaceutical iron drug Triferic was commercially launched in the U.S. September 2015 and is designed to prevent and treat iron deficiency anemia in end-stage renal disease patients.  As part of the our long-term growth strategy, the company is establishing global partnerships and licensing opportunities for world-wide distribution and sale of all it's therapies. 
Learn more 

Kidney Disease

Diseases of the kidney are a major health concern in the United States, affecting more than 30 million Americans and causing more than 100,000 deaths annually. Learn more 

Investor Center
Rockwell Medical's common shares are traded on NASDAQ under the symbol RMTI. More ››

About Us

Rockwell is a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. As an established manufacturer and leader in delivering high-quality hemodialysis concentrates to dialysis providers and distributors in the U.S. and abroad, Rockwell provides products used to maintain human life, removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. More »

Latest News

5/25/17 |Rockwell Medical Sends Important Message to Richmond Brothers' Clients: You Have the Sole Authority to Vote Your Own Shares.  Reminds Shareholders Not to be Misled by Richmond Brothers' Previous Claim to Control 11.8% of Rockwell.  Clarifies that David Richmond and Mark Ravich Each Personally Own Less Than 1% of Rockwell. Believes Richmond Brothers Has Made Misleading Statements While Promoting a Self-Serving Agenda to Gain Control of the Company. Urges Shareholders to Vote the WHITE Proxy Card Today to Keep Rockwell Strong and to Maximize Share Price.  Best Ways to Vote are Online or by Telephone

5/22/17 | Rockwell Medical Issues Letter to Shareholders Explaining Why Electing Mark Ravich Could Do Lasting Harm.  Urges Shareholders to Vote "FOR" David Domzalski on the WHITE Proxy Card

5/16/17 | Rockwell Medical Encourages Shareholders Not to Be Misled by Richmond Brothers.  Issues Letter to Shareholders Setting the Record Straight.  Urges Shareholders to Vote "FOR" David Domzalski on the WHITE Proxy Card

5/10/17 |Rockwell Medical Files Investor Presentation

5/9/17 | Rockwell Medical Reports First Quarter Results

5/9/17 | Rockwell Medical Shareholders Express Support for the Election of David Domzalski.  Rockwell Medical Urges Shareholders to Vote "FOR" David Domzalski and All Other Proposals on the WHITE Proxy Card

5/4/17 | Rockwell Medical Mails Letter to Shareholders Profiling Independent Director Nominee David Domzalski  Highlights: Experience Building Commercial Organizations and Launching New Drugs, President Foamix Pharmaceuticals USA.  Urges Shareholders to Vote "FOR" David Domzalski on the WHITE Proxy Card

4/21/17 | Rockwell Medical Files Definitive Proxy Materials. Mails Letter to Shareholders Highlighting Substantial Commercial Progress and Importance of Electing a Director with Relevant Pharmaceutical Expertise. Urges Shareholders to Vote "FOR" Rockwell Medical's Highly-Qualified Director Nominee David Domzalski on the WHITE Proxy Card

3/2/17 | Rockwell Medical Announces Nomination of David Domzalski to Board of Directors

See All the News »